UY32228A - Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones - Google Patents
Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicacionesInfo
- Publication number
- UY32228A UY32228A UY0001032228A UY32228A UY32228A UY 32228 A UY32228 A UY 32228A UY 0001032228 A UY0001032228 A UY 0001032228A UY 32228 A UY32228 A UY 32228A UY 32228 A UY32228 A UY 32228A
- Authority
- UY
- Uruguay
- Prior art keywords
- compounds
- compositions containing
- pirrolidine
- applications
- new class
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
La invención se refiere a una clase de compuestos de pirrolidina de fórmula (I), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. también se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (I) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del riñón poliquístico y el síndrome del ovario poliquístico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11286908P | 2008-11-10 | 2008-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32228A true UY32228A (es) | 2010-06-30 |
Family
ID=41503565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032228A UY32228A (es) | 2008-11-10 | 2009-11-09 | Nueva clase de compuestos de pirrolidina, composiciones conteniéndolas y aplicaciones |
Country Status (31)
Country | Link |
---|---|
US (1) | US8278343B2 (es) |
EP (1) | EP2364296A1 (es) |
JP (1) | JP2012508225A (es) |
KR (1) | KR20110083733A (es) |
CN (1) | CN102209710A (es) |
AP (1) | AP2011005728A0 (es) |
AR (1) | AR074314A1 (es) |
AU (1) | AU2009312427B2 (es) |
BR (1) | BRPI0920924A2 (es) |
CA (1) | CA2741589A1 (es) |
CL (1) | CL2011001034A1 (es) |
CO (1) | CO6382112A2 (es) |
CR (1) | CR20110217A (es) |
CU (1) | CU20110093A7 (es) |
DO (1) | DOP2011000127A (es) |
EA (1) | EA201100549A1 (es) |
EC (1) | ECSP11011032A (es) |
GE (1) | GEP20125607B (es) |
IL (1) | IL212490A0 (es) |
MA (1) | MA32782B1 (es) |
MX (1) | MX2011004903A (es) |
NI (1) | NI201100092A (es) |
NZ (1) | NZ592311A (es) |
PA (1) | PA8848001A1 (es) |
PE (1) | PE20110663A1 (es) |
SV (1) | SV2011003896A (es) |
TN (1) | TN2011000211A1 (es) |
TW (1) | TW201022234A (es) |
UY (1) | UY32228A (es) |
WO (1) | WO2010052625A1 (es) |
ZA (1) | ZA201104310B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201034675A (en) * | 2008-12-18 | 2010-10-01 | Sanofi Aventis | Method for treating macular degeneration |
TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ep2受體拮抗劑之新穎2h-吲唑 |
WO2013176220A1 (ja) * | 2012-05-25 | 2013-11-28 | 国立大学法人京都大学 | 概日リズム調整 |
CN110041269A (zh) * | 2019-05-16 | 2019-07-23 | 海门瑞一医药科技有限公司 | 一种2-氯-5-羟基嘧啶的制备方法 |
EP4359399A1 (en) * | 2021-06-24 | 2024-05-01 | Reservoir Neuroscience, Inc. | Ep2 antagonist compounds |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0133550B1 (ko) * | 1991-01-21 | 1998-04-23 | 요시또시 가즈오 | 3-벤질리덴-1-카르바모일-2-피롤리돈 유사체 |
ES2337887T3 (es) * | 2001-12-20 | 2010-04-30 | Merck Serono Sa | Derivados de pirrolidina en calidad de moduladores de prostaglandina. |
WO2007005176A1 (en) * | 2005-06-29 | 2007-01-11 | Allergan, Inc. | Pyrrolidinones for the treatment of glaucoma and ocular hypertension |
US7592364B2 (en) * | 2006-02-28 | 2009-09-22 | Allergan, Inc. | Substituted gamma lactams as therapeutic agents |
US7550448B2 (en) * | 2006-05-24 | 2009-06-23 | Allergan, Inc. | Therapeutic compounds |
DE102006039912A1 (de) * | 2006-08-25 | 2008-03-20 | Bayer Healthcare Ag | Substituierte Spirotetronsäuren und ihre Verwendung |
WO2008139287A1 (en) * | 2007-05-10 | 2008-11-20 | Pfizer Limited | Azetidine derivatives and their use as prostaglandin e2 antagonists |
-
2009
- 2009-10-30 MX MX2011004903A patent/MX2011004903A/es active IP Right Grant
- 2009-10-30 GE GEAP200912219A patent/GEP20125607B/en unknown
- 2009-10-30 KR KR1020117013231A patent/KR20110083733A/ko active IP Right Grant
- 2009-10-30 EA EA201100549A patent/EA201100549A1/ru unknown
- 2009-10-30 BR BRPI0920924A patent/BRPI0920924A2/pt not_active IP Right Cessation
- 2009-10-30 WO PCT/IB2009/054824 patent/WO2010052625A1/en active Application Filing
- 2009-10-30 CA CA2741589A patent/CA2741589A1/en not_active Abandoned
- 2009-10-30 PE PE2011001004A patent/PE20110663A1/es not_active Application Discontinuation
- 2009-10-30 CN CN2009801446055A patent/CN102209710A/zh active Pending
- 2009-10-30 JP JP2011535189A patent/JP2012508225A/ja not_active Ceased
- 2009-10-30 AU AU2009312427A patent/AU2009312427B2/en not_active Ceased
- 2009-10-30 NZ NZ592311A patent/NZ592311A/xx not_active IP Right Cessation
- 2009-10-30 EP EP09756838A patent/EP2364296A1/en not_active Withdrawn
- 2009-10-30 AP AP2011005728A patent/AP2011005728A0/xx unknown
- 2009-11-06 US US12/613,771 patent/US8278343B2/en not_active Expired - Fee Related
- 2009-11-09 UY UY0001032228A patent/UY32228A/es not_active Application Discontinuation
- 2009-11-09 PA PA20098848001A patent/PA8848001A1/es unknown
- 2009-11-09 TW TW098137955A patent/TW201022234A/zh unknown
- 2009-11-10 AR ARP090104350A patent/AR074314A1/es not_active Application Discontinuation
-
2011
- 2011-04-25 CU CU20110093A patent/CU20110093A7/es unknown
- 2011-04-26 CR CR20110217A patent/CR20110217A/es unknown
- 2011-04-26 IL IL212490A patent/IL212490A0/en unknown
- 2011-04-29 TN TN2011000211A patent/TN2011000211A1/fr unknown
- 2011-05-05 EC EC2011011032A patent/ECSP11011032A/es unknown
- 2011-05-06 SV SV2011003896A patent/SV2011003896A/es unknown
- 2011-05-06 DO DO2011000127A patent/DOP2011000127A/es unknown
- 2011-05-09 NI NI201100092A patent/NI201100092A/es unknown
- 2011-05-09 CL CL2011001034A patent/CL2011001034A1/es unknown
- 2011-05-10 MA MA33829A patent/MA32782B1/fr unknown
- 2011-05-11 CO CO11058068A patent/CO6382112A2/es not_active Application Discontinuation
- 2011-06-09 ZA ZA2011/04310A patent/ZA201104310B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US8278343B2 (en) | 2012-10-02 |
CO6382112A2 (es) | 2012-02-15 |
AR074314A1 (es) | 2011-01-05 |
US20100120793A1 (en) | 2010-05-13 |
CL2011001034A1 (es) | 2011-11-11 |
AP2011005728A0 (en) | 2011-06-30 |
CR20110217A (es) | 2011-05-12 |
SV2011003896A (es) | 2011-07-05 |
TW201022234A (en) | 2010-06-16 |
EA201100549A1 (ru) | 2011-12-30 |
ECSP11011032A (es) | 2011-06-30 |
AU2009312427A1 (en) | 2010-05-14 |
AU2009312427B2 (en) | 2011-10-20 |
JP2012508225A (ja) | 2012-04-05 |
KR20110083733A (ko) | 2011-07-20 |
MX2011004903A (es) | 2011-05-30 |
IL212490A0 (en) | 2011-06-30 |
MA32782B1 (fr) | 2011-11-01 |
EP2364296A1 (en) | 2011-09-14 |
CN102209710A (zh) | 2011-10-05 |
WO2010052625A1 (en) | 2010-05-14 |
NZ592311A (en) | 2012-12-21 |
GEP20125607B (en) | 2012-08-10 |
PA8848001A1 (es) | 2010-06-28 |
BRPI0920924A2 (pt) | 2016-10-04 |
CU20110093A7 (es) | 2012-01-31 |
NI201100092A (es) | 2011-10-31 |
DOP2011000127A (es) | 2011-07-15 |
TN2011000211A1 (fr) | 2012-12-17 |
PE20110663A1 (es) | 2011-09-23 |
CA2741589A1 (en) | 2010-05-14 |
ZA201104310B (en) | 2012-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019001714A1 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer. | |
PE20211427A1 (es) | Compuestos terapeuticos utiles para el tratamiento profilatico o terapeutico de una infeccion por el virus del vih | |
CO6321265A2 (es) | Compuestos de 2-amido-3-metil pirrolo pirimidinona fenilo -sustituidos como inhibidores bace-1 composiciones y su uso | |
PA8827901A1 (es) | Derivados de quinoxalin- y quinolin-carboxamida | |
ECSP11011032A (es) | Pirrolidinas | |
CU24487B1 (es) | Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror | |
SV2011003970A (es) | Derivados de sulfonamida | |
CY1116328T1 (el) | Παραγωγα 4 - αμινοπυριμιδινης και η χρηση τους ως ανταγωνιστων α2α υποδοχεων αδενοσινης | |
CR11061A (es) | Derivados de piridina | |
NI201400031A (es) | Derivados de ( 4 - fenilimidazol - 2 - il ) etilamina útiles como moduladores de canal de sodio | |
CL2012000925A1 (es) | Compuestos derivados de tetrahidrociclohepta[b]piridinilo, antagonista del receptor de cgrp; composicion farmaceutica que lo comprende; y su uso en el tratamiento de migraña, cefalea, diabetes, cancer, entre otras. | |
CL2009000368A1 (es) | 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3. | |
PA8623101A1 (es) | Compuestos farmaceuticamente activos | |
CR11101A (es) | Azetidinas | |
CY1122731T1 (el) | Διαμορφωτες υποδοχεα οιστρογονων | |
ECSP10010606A (es) | Derivados de quinuclidina como antagonistas de receptores muscarinicos m3 | |
ECSP22049160A (es) | Derivados de bencimidazol | |
CR9595A (es) | Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona | |
CO6690116A1 (es) | Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen | |
CL2017002969A1 (es) | Derivados de etinilo | |
CO6331339A2 (es) | Derivados de quinuclidina como antagonistas del receptor muscarinico m3 | |
CU20100217A7 (es) | Derivados de quinuclidina como antagonistas de receptores muscarínicos m3 | |
DOP2010000347A (es) | Derivados de quinuclidina como antagonistas de recpetores muscarinicos m3 | |
CY1114699T1 (el) | Νεα νουκλεοσιδια 7-δεαζαπουρινης για θεραπευτικες χρησεις |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181127 |